Overview

Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

Status:
Completed
Trial end date:
2019-09-24
Target enrollment:
Participant gender:
Summary
Primary Objective: To evaluate the pharmacokinetics (PK) of EXPAREL in pediatric subjects aged 6 to less than 17 years undergoing various types of surgeries. Secondary Objective: To evaluate the safety of EXPAREL in pediatric subjects aged 6 to less than 17 years undergoing various types of surgeries.
Phase:
Phase 3
Details
Lead Sponsor:
Pacira Pharmaceuticals, Inc
Treatments:
Bupivacaine